Biosimilars: Eight Is More Than Enough For FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eight pre-IND and IND applications for biosimilar products have been submitted to the Division of Therapeutic Proteins in CDER's Office of Biotechnology Products, according to division Director Amy Rosenberg.
You may also be interested in...
FDA “Busy” With Biosimilars; Sponsors Already In Pre-IND Meetings
Several sponsors appear to be taking advantage of the FDA’s biosimilar pathway, even though the agency has yet to clarify how it will handle the applications.
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.